We have been covering Pfizer’s antitrust suit against Johnson & Johnson (J&J), the manufacturer of Remicade® (infliximab). As we previously reported, Pfizer filed an antitrust lawsuit in September 2017 against J&J in the U.S. District Court for the Eastern District of Pennsylvania alleging that J&J has engaged in an anticompetitive scheme…
Last week, the U.S. Patent and Trademark Office issued a notice pursuant to the Coronavirus Aid, Relief, and Economic Security (CARES) Act. Specifically, “[u]ntil further notice, examiner and examining attorney interviews, Patent Trial and Appeal Board (PTAB) and Trademark Trial and Appeal Board (TTAB) oral hearings, and other similar in-person…
On March 13, 2020, Genentech and Amgen agreed to vacate all pre-trial deadlines and their April 20, 2020 trastuzumab biosimilar jury trial date, due to an issue with a document vendor. The parties’ stipulation was ordered by Judge Connolly on March 16, 2020. On March 18, because of the ongoing…
The COVID-19 pandemic has introduced new challenges for the pharmaceutical industry, including makers of biosimilars. In response, the FDA has asked pharmaceutical makers to closely monitor their supply chains and highlighted some of the ways the coronavirus could impact developmental pipelines. While the risk of supply chain disruptions is uncertain,…